跳至主要内容
临床试验/NCT05164263
NCT05164263招募中4 期

Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in Patients With Type II Diabetes Mellitus

Getz Pharma6 个研究点 分布在 5 个国家目标入组 2,000 人开始时间: 2021年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
2,000
试验地点
6
主要终点
SAFETY and TOLERABILITY Outcomes

研究概览

简要总结

Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.

Study design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.

Sample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal Infections, Nausea, Vomiting, Diarrhea, Abdominal Discomfort, Flatulence, Asthenia, Indigestion and Other side effects (if any).

Follow up visits: After recruitment, patient is supposed to have three visits for follow-ups.

Visit 1: 4 to 6 weeks of initiation of therapy. Visit 02: At 12 weeks of initiation of therapy. Visit 03: At 24 weeks of initiation of therapy.

LABORATORY TESTING:

Reputable Lab is considered for laboratory testing of diabetes patients i.e. HbA1C%, FBG, RFT and urine R/E. The certified clinical lab will be responsible for receiving and analyzing clinical sample. Patients will have special discount of upto 50% for study related laboratory investigations.

Where in Urine Routine Examination (Urine R/E), we consider as follows:

  • Visual Examination:

  • Urine color: Normal (Yellow), Pale Yellow, Dark Yellow, Brown, Red or Pink or any other.

  • Urine clarity: Clear, slightly Cloudy, cloudy or turbidity

  • Chemical Examination:

  • Specific gravity

  • pH

  • Bilirubin

  • Urobilinogen

  • Protein

  • Ketone

  • Leukocyte Esterase

  • Microscopic Examination:

  • Red Blood Cells:

  • Epithelial Cells:

  • Amorphous:

  • Pus Cells

  • Bacteria

  • Yeast

  • Casts

  • Crystals

Where in Renal Function Test (RFT), we consider as follows:

  • Blood Urea Nitrogen (BUN): mg/dL
  • Serum Creatinine: mg/dL
  • Estimated Glomerular Filtration Rate (eGFR): mL/min/1.73 m2

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informed consent. Patient uncontrolled on oral antidiabetics and lifestyle modification for at least 3 months. Patient who are empagliflozin naive. eGFR ˃60 mL/min/1.73m2.

排除标准

  • Type 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection, renal and/or hepatic dysfunctions, where RFT and Urine R/E is abnormal, Diabetic Ketoacidosis and/or hyperosmolar hyperglycemic state, severe hypoglycemia, Pregnant or lactating women, Pancreatitis, any serious complications or hypersensitivity.

研究组 & 干预措施

Empagliflozin naive uncontrolled T2DM on oral anti-diabetics & lifestyle modifications for 3 months

Experimental

Type 2 diabetic males & females between 18-65 years.

  • HbA1c: 7.0% - 10%
  • eGFR ˃60 mL/min/1.73m2.
  • Patient who will give informed consent

干预措施: Empagliflozin (Drug)

结局指标

主要结局

SAFETY and TOLERABILITY Outcomes

时间窗: 6 months

Frequency of adverse events, serious adverse events during the course of study follow-up. Percentage of patients who tolerate empagliflozin.

次要结局

  • Efficacy outcomes(6 months)

研究者

发起方
Getz Pharma
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

Real World Safety & Efficacy Experience of... | 临床试验